• Sign in

  • Join for free
  • Donate Today!
  • We are Social
    • Facebook
    • Twitter
    • Instagram
    • YouTube
    • LinkedIn
  • Who
    we are
    • Who we are
    • Our Story
    • Rosie
    • Rosie’s Blog
    • Our Trustees
    • Our Patrons
  • What
    we do
  • Secondary
    Breast Cancer
    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Your Stories
    • Where to go for information
  • Get
    involved
    • Our Fundraisers
    • How to fundraise
    • Events
      • Fonthill Open Garden Party
      • Past Events
  • News
    • News
    • In the media
    • Video
    • Rosie’s Blog
  • Contact
Secondary1st
  • Donate Today!

Search

Login

Register
  • 020 8905 3955info@secondary1st.org.uk
0
Secondary1st
  • Menu
  • Who
    we are
    • Who we are
    • Our Story
    • Rosie
    • Rosie’s Blog
    • Our Trustees
    • Our Patrons
  • What
    we do
  • Secondary
    Breast Cancer
    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Your Stories
    • Where to go for information
  • Get
    involved
    • Our Fundraisers
    • How to fundraise
    • Volunteer
    • Events
      • Fonthill Open Garden Party
      • Past Events
  • News & Media
    • News
    • In the media
    • Video
    • Rosie’s Blog
  • Contact
  • Donate Today!
01March

A Nice recommendation

Next
Previous
March 01, 2021
By cuco_admin_sec
0 Comment

Nice, the National Institute for Health and Care Excellence, has recommended the use of ribociclib, also known as Kisqali for routine use by the NHS in England and Wales, after it was originally made available through the Cancer Drugs Fund.  Their draft guidance recommends ribociclib plus fulvestrant as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.  The combination is recommended for adults who have had previous endocrine therapy and where exemestane plus everolimus is the most appropriate alternative treatment.  Ribociclib is to be taken once a day as a pill and is a type of drug called a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. These work by inhibiting proteins in cancer cells, and so prevent the cells from dividing and growing.   It is believed that the different side effects of each of the CDK4/6 inhibitors, which are generally less toxic than the combination of exemestane and everolimus, mean that people would like to have a range of treatment options available to them.  Subject to appeal, NICE’s final guidance will be published in March 2021.

Categories: News
  • Search

  • Sign up for Newsletter

    * = required field
  • Categories

    • Event
    • Fundraising
    • In the media
    • News
    • Past Events
    • Rosie's blog
    • Uncategorised
    • Your Stories
  • Latest News

    • Walking the Wall

      June 09, 2022

    • A New Breast Cancer Drug

      June 09, 2022

    • Carol goes Ziplining at Eighty

      May 09, 2022

    • Lucy, Lara, Anoushka, Alexander, Theo, Elica and Emily Go Cycling

      May 09, 2022

  • Who We Are

    • Who we are
    • Our Story
    • Rosie
    • Rosie’s blog
    • Our Trustees
    • Our Patrons
  • What We Do

    • What we do
  • Secondary Breast Cancer

    • What is secondary breast cancer?
    • Symptoms
    • What is the current treatment
    • Maximising quality of life
    • Where to go for information
  • Get Involved

    • How to fundraise
    • Our Fundraisers

© 2016 - 2022 Secondary First is a Company Limited by Guarantee. Registered in England and Wales No. 9920657. Registered Office: 1st Floor Healthaid House, Marlborough Hill, Harrow, HA1 1UD. It is a Registered Charity Number 1165614.
Site maintained by CuCo Creative.

  • Cookie Policy
  • Privacy Policy